Lexaria Bioscience (CSE: LXX-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive with news the company has received ethics board approval to conduct a pilot human pharmacokinetic exploratory study of antiviral drugs that have previously been studied against other coronavirus strains, comparing Lexaria's DehydraTECH formulations to controls without Lexaria's technology.
Bunka telling Proactive how the study will work and also what the timing looks like as they have a few more steps to go through.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE